Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Fight Escalates As Biden Administration Seeks Refunds From Manufacturers, Threatens Them With Fines

Executive Summary

Lilly, AstraZeneca, Novartis, Sanofi, Novo Nordisk and United Therapeutics ordered by HRSA to resume discounts to 340B contract pharmacies and refund past 'overcharges.'

You may also be interested in...



340B Court Ruling Offers Manufacturers Short-Term Reprieve In Contract Pharmacy Dispute

Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.

HHS Weighs Fines For 340B Restrictions; AstraZeneca Says They Could Reach $530M Per Month

US government moves ahead with enforcement action while several court decisions remain pending on the viability of its interpretation of the law governing the 340B outpatient drug discount program. Underscoring industry’s confidence in its opposing view, Merck & Co. recently joined the companies that are restricting discounts to contract pharmacies.

Pharma’s 340B Dispute Resolution Arguments May Get Boost From Supreme Court’s Patent Ruling

As stakeholders begin to mull the impact of the Arthrex opinion, HHS withdraws its advisory opinion concluding manufacturers are legally bound to provide 340B discounts to contract pharmacies, and Lilly takes aim at 340b contract pharmacy ‘replenishment’ model.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel